Adverse Events with Obesity Drugs (GLP-1s): Management Guide

What adverse events do GLP-1 obesity drugs actually cause?

Gastrointestinal reactions dominate. In the Wegovy weight-management trials, which treated 2,116 adults with the 2.4 mg weekly injection for up to 68 weeks, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11% [1].

The oral GLP-1 drug orforglipron (Foundayo) shows the same pattern at its 17.2 mg dose: nausea 35% versus 10%, diarrhea 25% versus 11%, vomiting 24% versus 4% and constipation 24% versus 9% [2]. Any gastrointestinal adverse reaction was reported by 69% of patients on 17.2 mg versus 37% on placebo [2].

Tirzepatide acts on both GIP and GLP-1 receptors, and its label reports nausea 28%, diarrhea 23%, vomiting 13% and constipation 11% at 15 mg versus 8%, 8%, 2% and 5% on placebo in pooled weight-management trials [3]. Each label cautions that adverse reaction rates from different trials cannot be directly compared, so these figures are not a ranking [1][2].

These reactions are also the leading reason people stop treatment: 6.8% versus 3.2% for Wegovy, 8% versus 3% for Foundayo, and 6.7% versus 3.4% for Zepbound 15 mg [1][2][3]. Most of the Foundayo discontinuations (5%) were for gastrointestinal reactions [2].

Why dose escalation is the labeled management tool

Both weight-management labels build the start of treatment around GI tolerance. Wegovy injection begins at 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg and 1.7 mg at 4-week intervals, with 1.7 mg or 2.4 mg (recommended) as the maintenance dose for weight reduction in adults; the label states that this escalation is followed to reduce the risk of gastrointestinal adverse reactions [1]. It adds that if a patient does not tolerate a dose during escalation, delaying escalation for 4 weeks can be considered [1].

Foundayo starts at 0.8 mg once daily and moves to 2.5 mg and then 5.5 mg after at least 30 days at each dose, then to 9, 14.5 or 17.2 mg at intervals of at least 30 days based on response and tolerability, to a maximum of 17.2 mg daily [2]. Its label notes that nausea, vomiting and diarrhea were more frequent during the escalation period and decreased over time [2].

Severe GI reactions are uncommon but labeled: about 3% of orforglipron-treated patients versus 1% on placebo in the pooled weight trials, with 3%, 6% and 6% of patients on 5.5, 9 and 17.2 mg stopping for a GI reaction versus 0.7% on placebo [2]. Both labels say the drugs are not recommended in people with severe gastroparesis, and the labels do not say GLP-1 drugs cause gastroparesis [1][2].

Diarrhea, constipation, reflux and hair loss

Upper GI complaints are common alongside nausea. At the 17.2 mg Foundayo dose, the label records dyspepsia in 13% versus 4%, abdominal distension in 8% versus 3%, eructation in 8% versus 1%, gastroesophageal reflux disease in 7% versus 2% and flatulence in 6% versus 2% [2]. The Wegovy label lists dyspepsia in 9% versus 3% and reflux disease in 5% versus 3% [1].

Hair loss is labeled too, and is more frequent in women: 3% versus 1% with Wegovy 2.4 mg, 5% versus 2% with Foundayo 17.2 mg (7% of women versus 0.9% of men), and 4% to 5% versus 1% with Zepbound [1][2][3].

Both labels describe the drugs as an adjunct to a reduced-calorie diet and increased physical activity, and the labels' tool for GI side effects is paced titration [1][2].

When is stomach pain a pancreatitis warning?

The GLP-1 labels warn about acute pancreatitis. The Wegovy label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Wegovy if pancreatitis is suspected [1]. The Foundayo label gives the same instruction [2].

In the pooled Foundayo weight-management trials, 6 acute pancreatitis events confirmed by adjudication occurred in orforglipron-treated patients (0.14 per 100 patient-years of exposure) versus 2 events in 1 placebo-treated patient (0.04 per 100 patient-years) [2].

The contraindications in these two labels are a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to the drug or an ingredient [1][2].

Gallbladder, kidneys and blood pressure

Wegovy treatment is associated with more gallbladder disease. In adult weight-management trials, cholelithiasis was reported by 1.6% versus 0.7% on placebo and cholecystitis by 0.6% versus 0.2%, and the label notes higher rates in adolescents aged 12 and older (cholelithiasis 3.8% versus 0%) [1]. With Foundayo, cholelithiasis was reported in 1% versus 0.7% and acute cholecystitis in 0.4% [2].

Acute kidney injury from volume depletion is a labeled warning for the class. The Wegovy label says to monitor renal function in patients reporting reactions that could lead to volume depletion [1]. In the Foundayo trials, acute kidney injury was reported in 0.2% versus 0.05%, and hypotension in 2% versus 0.5%, with 4% among patients also taking antihypertensives versus 1% among those not [2].

Hypoglycemia when combined with insulin or a sulfonylurea

GLP-1 drugs raise the risk of hypoglycemia when combined with insulin or an insulin secretagogue such as a sulfonylurea, and both labels say to consider reducing the dose of the insulin or secretagogue when starting [1][2]. In the Foundayo type 2 diabetes trial, plasma glucose below 54 mg/dL was reported in 2% versus 0.2% on placebo, and 7% of patients taking Foundayo with a sulfonylurea reported hypoglycemia versus 0.5% of those not taking one [2].

Heart rate, surgery and other labeled warnings

Resting heart rate rises modestly: a mean of 1 to 4 bpm with Wegovy, 4 to 5 bpm with Foundayo versus 0.5 bpm on placebo, and 1 to 3 bpm with tirzepatide; the Wegovy label says to monitor heart rate at regular intervals [1][2][3].

Rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation appear in both labels, with instructions for patients to inform healthcare providers of any planned surgery or procedure [1][2].

The class boxed warning covers thyroid C-cell tumors in rodents, with human relevance undetermined, and both labels state that routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma [1][2]. Orforglipron's boxed warning uses different wording because it is not pharmacologically active in rats or mice and produced no rodent tumors [2].

Diabetic retinopathy complications are a labeled warning in patients with type 2 diabetes [1]. In the European Union, semaglutide product information lists non-arteritic anterior ischemic optic neuropathy as a very rare side effect, up to 1 in 10,000 people; US semaglutide labels do not list it [4][1].

FDA reviewed the risk of suicidal ideation and behavior, found no increased risk across a meta-analysis of 91 placebo-controlled trials (107,910 patients) and a cohort of about 2.24 million new users, and in January 2026 asked makers to remove that warning from Saxenda, Wegovy and Zepbound [5].

Both labels state that weight loss offers no benefit in pregnancy and to discontinue when pregnancy is recognized; the Wegovy label advises stopping at least 2 months before a planned pregnancy [1][2].

Missing doses, stopping, and combining drugs

The Foundayo label says to take a missed dose as soon as possible, not to double the next dose, and to reinitiate escalation at a lower dose if 7 or more consecutive doses are missed [2].

The Wegovy label states that combining Wegovy with another GLP-1 receptor agonist is not recommended, and the Foundayo label carries the same limitation of use [1][2].

Stopping has a measurable cost. In STEP 4, 803 adults who had reached semaglutide 2.4 mg weekly were randomized to continue or switch to placebo for 48 weeks: those who continued lost a further 7.9% of body weight, while those switched to placebo gained 6.9% [6].